Short answer
Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on July 31, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Soleno acquisition closed May 18, 2026 at $53.00 per share, adding VYKAT XR for Prader-Willi syndrome.
Neurocrine Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Soleno acquisition closed May 18, 2026 at $53.00 per share, adding VYKAT XR for Prader-Willi syndrome
- Pro forma revenue $3,050.9M in 2025, including $190.4M from Soleno
- Pro forma net income $324.5M in 2025, with diluted EPS $3.17 after acquisition-related amortization
- VYKAT XR valued at $2,237.8M, creating $139.9M of 2025 pro forma amortization expense
- Acquisition funded through a $1.0B revolving facility, with $600.0M drawn at 4.896% and fully repaid by June 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurocrine Biosciences Inc 8-K filings
Get the next NBIX 8-K as it lands
Follow NBIX for push alerts, or ask the research agent what this filing means.